IMDX vs XBIO

Head-to-Head Stock Analysis & Investment Rating

Last Updated: Sep 29, 2026

IMDX

37.5
AI Score
VS
XBIO Wins

XBIO

62.5
AI Score

Investment Advisor Scores

IMDX

38score
Recommendation
AVOID NEW MONEY

XBIO

63score
Recommendation
HOLD

AI Analyst Insights

Detailed Metrics Comparison

Metric IMDX XBIO Winner
Forward P/E 0 0 Tie
PEG Ratio 0 0 Tie
Revenue Growth -53.9% 12.0% XBIO
Earnings Growth 0.0% 0.0% Tie
Tradestie Score 37.5/100 62.5/100 XBIO
Profit Margin 0.0% -75.9% IMDX
Beta 1.00 1.00 Tie
AI Recommendation AVOID NEW MONEY HOLD XBIO

Relative Price Performance (Last 90 Days)

IMDX 1M: -10.5% · 3M: -40.2% XBIO 1M: -47.8% · 3M: -20.2%

Current Technical Phase

IMDX

Markdown
Sell / avoid

Price below a falling SMA50 (slope -10.4%), weak momentum, RSI 40

RSI (14): 39.5 · Price: $3.44

XBIO

Neutral
Hold

Mixed signals - no dominant trend phase, RSI 34

RSI (14): 34.4 · Price: $2.21

Fundamentals Snapshot

Metric IMDX XBIO
Market Cap — —
Forward P/E -4.5 -6.8
Trailing P/E — —
Revenue (TTM) — —
Revenue Growth -0.5% 0.1%
Gross Margin 0.5% 1.0%
Operating Margin -38.2% -1.5%
EPS -1.62 -1.15
Dividend Yield — —

Frequently Asked Questions

Based on our detailed analysis, XBIO is currently the stronger investment candidate based on our comprehensive scoring model.

We analyze revenue and earnings growth rates in the "Growth" section above. Generally, the company with higher year-over-year revenue and EPS growth is fostering better expansion. Check the table above for the specific growth percentages.

Valuation is determined by metrics like the P/E Ratio and PEG Ratio. A lower P/E typically suggests a stock is cheaper relative to its earnings. Refer to the "Valuation" section in our comparison table to see which stock currently trades at a more attractive multiple.